Erudio Healtherudio.com
Drug
Retifanlimab trials: what clinicians said in public
No HCP commentary report on a trial studying retifanlimab yet. Erudio has found public clinician commentary on 3 clinical trials studying retifanlimab: FIGHT-101, INCB161734-101 and InterAACT 2. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| InterAACT 2 NCT04472429 · Incyte Corporation DeepView → | locally recurrent or metastatic squamous cell anal carcinoma | Phase 3 | Deep | View | |||
| FIGHT-101 NCT02393248 · Incyte Corporation DeepView → | advanced malignancies | Phase 1/Phase 2 | Deep | View | |||
| INCB161734-101 NCT06179160 · Incyte Corporation FocusedView → | KRAS G12D-mutated advanced or metastatic solid tumors | Phase 1 | Focused | View | |||